Author Archives: Marisa Wexler

Roche Helps Bring NMOSD Patient Day to China

The Illness Challenge Foundation (ICF) sponsored the second annual Asia-Pacific NMOSD Patient Day in Beijing, China, to increase awareness and improve care for those living with neuromyelitis optica spectrum disorder (NMOSD). The May 25 event brought together NMOSD patients, neurologists and other healthcare professionals, and representatives from a variety…

Uplizna Reduced Disability Progression in Patients During Trial

Treatment with Uplizna (inebilizumab-cdon) can reduce disability progression in people with neuromyelitis optica spectrum disorder (NMOSD), findings from the N-MOmentum clinical trial show. The results were published in Neurology Neuroimmunology & Neuroinflammation, in a study, “Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis…

#AANAM – Soliris Has Long-term Relapse Prevention

Soliris (eculizumab) significantly reduced the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) over nearly three years, according to new data from the clinical trial PREVENT and its extension study. Additional findings project that long-term Soliris treatment may reduce relapse risk over the course of…

CBJF Works to Increase Education, Awareness, Research

In summer 2014, 22-year-old Connor Judge was working as a landscaper when he experienced unusual pain in his legs and back. At first, the symptoms were presumed to be related to his landscaping work; visits to a few general practitioners were unremarkable. Then, on Aug. 29,…

#ACTRIMS2021 – Expert Lectures About Available NMOSD Treatments

An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…

#ACTRIMS2021 – Complex Ways That AQP4-IgG Drives NMOSD Detailed

In most people with neuromyelitis optica spectrum disorder (NMOSD), autoantibodies against aquaporin-4 (AQP4) coordinate a complex series of immune activities that drive the disease. Better understanding of these disease-causing mechanisms may help in efforts to find new treatments for NMOSD patients. These mechanisms were explained in the lecture, “…

Dysphagia May Be Sign of Brain Damage in NMOSD and MOGAD Patients

People with neuromyelitis optica spectrum disorder (NMOSD) with difficulty swallowing are more likely to have clinical signs of brain involvement and more extensive disability, a small study suggests. Measures of a patient’s difficulty with swallowing could be used to indirectly assess brain involvement in NMOSD and the related disorder…